NICE sits at the center of two critical enterprise markets: customer experience and financial crime prevention. This piece breaks down what is changing inside the business and why its next phase of cloud and AI adoption matters for investors.
Over the past six months, Hologic has been a great trade, beating the S&P 500 by 20%. Its stock price has climbed to $74.17, representing a healthy 31.3% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date rallies.
Medical technology company Hologic (NASDAQ:HOLX) announced better-than-expected revenue in Q3 CY2025, with sales up 6.2% year on year to $1.05 billion. Its non-GAAP profit of $1.13 per share was 2.7% above analysts’ consensus estimates.
Shares of medical technology company Hologic (NASDAQ:HOLX) jumped 3.1% in the afternoon session after the company announced it agreed to be acquired by private equity firms Blackstone and TPG in a deal that takes the company private.
